Trial Profile
An Explorative Study of Tolerability and Pharmacokinetics of SU011248 In Combination With Docetaxel As First-Line Treatment in Patients With Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Sunitinib (Primary)
- Indications Advanced breast cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 01 Apr 2009 Actual patient number (22) added as reported by ClinicalTrials.gov.
- 01 Apr 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
- 01 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.